Cure8 research brief
This pooled analysis focuses on children with IBD and reports that ustekinumab was associated with substantial clinical and steroid-free remission rates and a low incidence of serious adverse events—information that may affect treatment choices for pediatric patients who did not respond to other biologics.
Pediatric patients with IBD and their caregivers, pediatric gastroenterologists and clinicians who manage biologic therapy, and researchers interested in pediatric IBD treatment options.
The paper is a systematic review and meta-analysis of 21 studies including 839 pediatric IBD patients treated with ustekinumab. Reported pooled outcomes include 52-week clinical remission (~61%), steroid-free remission (~53%), 52-week clinical response (~55%), and an endoscopic remission rate (~38%). Serious adverse events were reported as uncommon (~1%).
The analysis authors judged results robust and did not detect significant publication bias. The report suggests ustekinumab may be an effective option for children with IBD, including those who failed or were intolerant to prior biologics.
This article is an abstract/preprint-level meta-analysis (structured content depth: abstract), so it summarizes pooled evidence rather than presenting new trial-level data.
The article is presented as an abstract-level meta-analysis (preprint) on Europe PMC. Results are pooled from multiple studies with variable designs; the record has not completed peer review, so findings should be interpreted cautiously and discussed with clinicians.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
The trial tests ustekinumab dosing, safety, and pharmacokinetics specifically in children with moderate–severe Crohn’s — information that can affect pediatric treatment options and dosing guidance once results are...
